Prof Demin Zhou from Peking University in China conducts a proof-of-principle study, showing that a genetic method will improve live virus vaccine development. You can get to know more about the study in the journal Science. In the study, live viruses are genetically manipulated to activate the immune system without harming healthy cells. The vaccine produced by this method effectively protects experimental animals from influenza viruses. The method may also be applied to other viruse vaccines, such as vaccines to Ebola, HIV, and Zika. Live attenuated vaccines are generally very potent -- they elicit strong cellular and antibody responses. But the living microbes that have been weakened still have the potential to revert to their virulent form and cause disease, which limits their use. If a method can lower their toxicity to make them safe and maintain their ability to trigger strong immune response, it will revolutionize the development of vaccine. In the work, first author Longlong Si changed the genome of influenza A viruses to make them unable to replicate in conventional cells but able to activate the immune system. They tested the modified viruses in animals including mice, guinea pigs, and ferrets. When the animals received one dose of the modified viruses, it triggered an antibody response. A second dose greatly increased the production of antibodies in the animals. Such viruses also provided protection against other strains of influenza. If the method works in humans, a useful solution to stop viral infection has been found. More research is needed before testing the method in clinical trials. Influenza viruses are responsible for the disease flu, which leads to fever, coughing, sore throat, running nose, muscle aches and other symptoms. Almost everyone have the chance to have flu. During flu season, people are susceptible to the disease. Vaccines that more effectively prevent flu infecion will provide protection against the virus, saving people's lives and reducing health burden. Antibody and protein such as rabbit polyclonal antibody can be offered by CusAb.